Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

##STR00001##

Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

##STR00001##

The present technology is directed to compounds Formulas I, II, III, and IV as well as compositions that include one or more of the compounds and methods of making the compounds. In particular, the present compounds may be used as a replacement for NMP in compositions to produce lower toxicity compositions.

##STR00001##

The present technology is directed to compounds Formulas I, II, III, and IV as well as compositions that include one or more of the compounds and methods of making the compounds. In particular, the present compounds may be used as a replacement for NMP in compositions to produce lower toxicity compositions.

##STR00001##

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Dual cation hydrate inhibitor compositions and methods of using such compositions to, for example, inhibit the formation of gas hydrate agglomerates are provided. In some embodiments, such methods include introducing a hydrate inhibitor composition into a fluid, wherein the hydrate inhibitor composition includes at least one compound having the structural formula: ##STR00001##
wherein each of R.sup.1, R.sup.2, and R.sup.3 is independently a C.sub.1 to C.sub.6 hydrocarbon chain, wherein R.sup.4 is selected from the group consisting of hydrogen and any C.sub.1 to C.sub.50 hydrocarbon chain, wherein each of R.sup.5 and R.sup.6 is independently selected from the group consisting of hydrogen and a C.sub.1 to C.sub.50 hydrocarbon chain, wherein X.sup.− and Y.sup.− are counter anions, and wherein each of a and b is independently an integer from 1 to 10.

Dual cation hydrate inhibitor compositions and methods of using such compositions to, for example, inhibit the formation of gas hydrate agglomerates are provided. In some embodiments, such methods include introducing a hydrate inhibitor composition into a fluid, wherein the hydrate inhibitor composition includes at least one compound having the structural formula: ##STR00001##
wherein each of R.sup.1, R.sup.2, and R.sup.3 is independently a C.sub.1 to C.sub.6 hydrocarbon chain, wherein R.sup.4 is selected from the group consisting of hydrogen and any C.sub.1 to C.sub.50 hydrocarbon chain, wherein each of R.sup.5 and R.sup.6 is independently selected from the group consisting of hydrogen and a C.sub.1 to C.sub.50 hydrocarbon chain, wherein X.sup.− and Y.sup.− are counter anions, and wherein each of a and b is independently an integer from 1 to 10.

The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them

##STR00001##

The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them

##STR00001##